Hemangioblastoma

Hemangioblastomas are rare, benign, highly vascular WHO grade I tumors that primarily involve the central nervous system (CNS). These tumors most commonly develop in the cerebellum, followed by the spinal cord and brainstem, and can be sporadic or associated with von Hippel-Lindau (VHL) disease, an autosomal dominant genetic disorder that predisposes individuals to the formation of various tumors. Approximately 45% of people with VHL disease develop CNS hemangioblastomas, with an estimated 20% of those with CNS hemangioblastomas having concurrent VHL disease. Hemangioblastomas are uncommon, representing 1% to 2.5% of all brain tumors and 2% to 10% of spinal cord tumors, and typically present between the ages of 30 and 60 years with a slight male predominance. The clinical presentation of hemangioblastomas varies depending on their location in the CNS and can significantly impact quality of life. Cerebellar tumors will often cause headaches, nausea, vomiting, and signs of increased intracranial pressure, whereas brainstem tumors can cause motor and sensory deficits, ataxia, and potentially fatal intracerebral hemorrhage. Spinal hemangioblastomas may present with localized pain, motor weakness, sensory disturbances, and dysfunction of the bowel or bladder. The diagnosis is typically made using magnetic resonance imaging (MRI), which usually reveals a cystic mass with a contrast-enhancing mural nodule. The primary treatment for these tumors is surgical resection, with preoperative embolization being used occasionally due to the vascularity of the tumor. Stereotactic radiosurgery and novel agents targeting vascular endothelial growth factor pathways are potential treatments for multiple or surgically inaccessible tumors. The prognosis following surgery is usually favorable, with recurrence rates of less than 25%, although routine clinical follow-up is essential, particularly in patients with VHL disease.